Journal of the Neurological Sciences
Volume 215, Issue 1 , Pages 51-55 , 15 November 2003

Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism

  • George P. Paraskevas

      Affiliations

    • Department of Neurology, Athens National University, Medical School, Aeginition Hospital, 74 Vas. Sophias Avenue, Athens 11528, Greece
    • ,
  • Elisabeth Kapaki

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +30-210-7289125; fax: +30-210-9811638.
    • Department of Neurology, Athens National University, Medical School, Aeginition Hospital, 74 Vas. Sophias Avenue, Athens 11528, Greece
    • ,
  • Olga Petropoulou

      Affiliations

    • Department of Neurology, Athens National University, Medical School, Aeginition Hospital, 74 Vas. Sophias Avenue, Athens 11528, Greece
    • ,
  • Maria Anagnostouli

      Affiliations

    • Department of Neurology, Athens National University, Medical School, Aeginition Hospital, 74 Vas. Sophias Avenue, Athens 11528, Greece
    • ,
  • Vasileios Vagenas

      Affiliations

    • Neurological Clinic, First Hospital of Social Insurance Institution, Athens, Greece
    • ,
  • Constantine Papageorgiou

      Affiliations

    • Department of Neurology, Athens National University, Medical School, Aeginition Hospital, 74 Vas. Sophias Avenue, Athens 11528, Greece
    • Deceased.

Received 20 March 2003 ,Accepted 6 June 2003.

References 

  1. Dugan LL, Choi DW. Excitotoxicity, free radicals and cell membrane changes. Ann. Neurol. 1994;35:S17–S21
  2. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998;44(Suppl. 1):S72–S84
  3. Niki E. Vitamin C as an antioxidant. World Rev. Nutr. Diet. 1991;64:1–31
  4. Grünewald RA. Ascorbic acid in the brain. Brain Res. Rev. 1993;18:123–133
  5. Niki E, Yamamoto Y, Takahashi M, et al.  Inhibition of oxidation of biomembranes by tocopherol. In:  Diplock AT,  Machlin LJ,  Packer L,  Pryor WA editor. Vitamin E: biochemistry and health implications. vol. 570:New York: Ann. NY Acad. Sci; 1989;p. 23–31
  6. Das NP. Effects of vitamin A and its analogs on nonenzymatic lipid peroxidation in rat brain mitochondria. J. Neurochem. 1989;52:585–588
  7. Senarath-Yapa SC. Detection of subclinical ascorbate deficiency in early Parkinson's disease. Public Health. 1992;106:393–395
  8. Singh RB, Niaz MA, Grosh S, et al.  Dietary intake and plasma levels of antioxidant vitamins in health and disease. A hospital-based case-control study. J. Nutr. Environ. Med. 1995;5:235–242
  9. Férnandez-Calle P, Jiménez-Jiménez FJ, Molina JA, et al.  Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease. J. Neurol. Sci. 1993;118:25–28
  10. King D, Playfer JR, Roberts MB. Concentrations of vitamins A, C and E, in elderly patients with Parkinson's disease. Postgrad. Med. J. 1992;68:634–637
  11. Logroscino G, Marder K, Cote L, et al.  Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-controlled study. Ann. Neurol. 1996;39:89–94
  12. DeRijk MC, Breteler MMB, den Breeijen JH, et al.  Dietary antioxidants and Parkinson's disease. Arch. Neurol. 1997;54:762–765
  13. Férnandez-Calle P, Molina JA, Jiménez-Jiménez FJ. Serum levels of α-tocopherol (vitamin E) in Parkinson's disease. Neurology. 1992;42:1064–1066
  14. Hellenbrand W, Boeing H, Robra B-P, et al.  Diet and Parkinson's disease: II. A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:644–650
  15. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793–795
  16. Riemersma RA, Wood DA, Macintyre CCA, et al.  Low plasma vitamins E and C. Increased risk of angina in Scottish men. In:  Diplock AT,  Machlin LJ,  Packer L,  Pryor WA editor. Vitamin E: biochemistry and health implications. vol. 570:New York: Ann. NY Acad. Sci; 1989;p. 291–295
  17. Foltynie T, Barker R, Brayne C. Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology. 2002;21:1–7
  18. Winikates J, Jancovic J. Clinical correlates of vascular parkinsonism. Arch. Neurol. 1999;56:98–102
  19. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct heterogeneous clinical entity. Acta Neurol. Scand. 2001;104:63–67
  20. Jellinger KA. Vascular parkinsonism—neuropathological findings. Acta Neurol. Scand. 2002;105:414–415
  21. Riley DE, Lang AE. Non-Parkinson akinetic-rigid syndromes. Curr. Opin. Neurol. 1996;9:321–326
  22. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria of Parkinson's disease. Arch. Neurol. 1999;56:33–39
  23. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol. Scand. 1994;89:242–251
  24. Gilman S, Low PA, Quinn N, et al.  Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 1999;163:94–98
  25. Litvan I, Agid Y, Calne D, et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1–9
  26. Paraskevas GP, Kapaki E, Libitaki G, et al.  Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol. Scand. 1997;96:88–90
  27. Dexter DT, Ward RJ, Wells FR, et al.  α-Tocopherol levels in brain are not altered in Parkinson's disease. Ann. Neurol. 1992;32:591–593
  28. Molina JA, De Bustos F, Jimenez-Jimenez FJ, et al.  Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease. J. Neural Transm. 1997;104:1287–1293
  29. Riederer P, Sofic E, Rausch WD, et al.  Transision metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J. Neurochem. 1989;52:515–520
  30. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 1994;33:419–425
  31. Paraskevas GP, Kapaki E, Zournas C, et al.  Copper and ascorbate in Parkinson's disease. In: Proceedings Book of the “International Symposium on Trace Elements in Human: New Perspectives”. Athens. 1997;p. 559–568
  32. Chiueh CC, Miyake H, Peng MT. Role of dopamine autooxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. In:  Narabayashi H,  Nagatsu T,  Yanagisawa N,  Mizuno Y editor. Advances in neurology. Parkinson's disease. vol. 60:New York: Raven Press; 1993;p. 251–258
  33. Li CL, Werner P, Cohen G. Lipid peroxidation in brain: interaction of l-dopa/dopamine with ascorbate and iron. Neurodegeneration. 1995;4:147–153
  34. Albers DS, Augood SJ, Park LC, et al.  Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J. Neurochem. 2000;74:878–881
  35. Simon JA, Hudes ES, Browner WS. Serum ascorbic acid and cardiovascular disease prevalence in U.S. adults. Epidemiology. 1998;9:316–321
  36. Gey KF, Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. In:  Diplock AT,  Machlin LJ,  Packer L,  Pryor WA editor. Vitamin E: biochemistry and health implications. vol. 570:New York: Ann. NY Acad. Sci; 1989;p. 268–282
  37. Knekt P, Reunanen A, Jarvinen R, et al.  Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol. 1994;139:1180–1189
  38. Pierdomenico SD, Costantini F, Bucci A, et al.  Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension. Hypertension. 1998;31:621–626
  39. Tse WY, Maxwell SR, Thomason H, et al.  Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J. Hum. Hypertens. 1994;8:843–849
  40. Sharpe PC, Mulholland C, Trinick T. Ascorbate and malondialdehyde in stroke patients. Ir. J. Med. Sci. 1994;163:488–491
  41. Schmidt R, Fazekas F, Hayn M, et al.  Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J. Neurol. Sci. 1997;152:15–21
  42. Hirano R, Kondo K, Iwamoto T, et al.  Effects of antioxidants on the oxidative susceptibility of low-density lipoprotein. J. Nutr. Sci. Vitaminol. 1997;43:435–444
  43. Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB. 1994;8:1279–1284
  44. Stocker R. Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr. Opin. Lipidol. 1994;5:422–433
  45. Karpen CW, Merola AJ, Trewyn RV, et al.  Modulation of platelet thromboxane A2 and arterial prostacyclin by dietary vitamin E. Prostaglandins. 1981;22:651–661
  46. Fukuzawa K, Kurotori Y, Tokumura A, Tsukatani H. Increased platelet-activating factor (PAF) synthesis in polymorphonuclear leucocytes of vitamin E-deficient rats. In:  Diplock AT,  Machlin LJ,  Packer L,  Pryor WA editor. Vitamin E: biochemistry and health implications. vol. 570:New York: Ann. NY Acad. Sci; 1989;p. 449–454
  47. Chang JY, Liu LZ. Neurotoxicity of cholesterol oxides on cultured cerebellar granule cells. Neurochem. Int. 1998;32:317–323
  48. Chang JY, Phelan KD, Chavis JA. Neurotoxicity of 25-OH-cholesterol on sympathetic neurons. Brain Res. Bull. 1998;45:615–622

PII: S0022-510X(03)00184-9

doi: 10.1016/S0022-510X(03)00184-9

Journal of the Neurological Sciences
Volume 215, Issue 1 , Pages 51-55 , 15 November 2003

Article Tools

* Image Usage & Resolution